Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase II RESIST study of MAP-4343 begins in patients with drug-resistant depression

Oct. 14, 2019

Metformin rejuvenates stem cells, restores CNS remyelination

Oct. 14, 2019

Aruna Bio receives support for preclinical development of AB-126

Oct. 11, 2019

NIH gives grant to Oligomerix to develop inhibitors of tau olgomer formation

Oct. 11, 2019

SiteOne Therapeutics wins grant to support development of lead candidate for postoperative pain

Oct. 11, 2019

Dual voltage-gated calcium channel and mu-opioid receptor ligands revealed in Esteve patent

Oct. 11, 2019

SCR-2682 demonstrates promising activity in rodent MES-induced seizure models

Oct. 11, 2019

First patient dosed in phase I study of ALD-1910

Oct. 11, 2019

FDA accepts IND application for EC-5026 for the treatment of pain

Oct. 11, 2019

DSMB recommends continuation of phase IIa study of montelukast VersaFilm in Alzheimer's disease

Oct. 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...